Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients

Patients with degenerative disc disease may suffer from chronic lumbar discogenic (DP) or radicular leg (RLP) pain. Minimally invasive DiscoGel therapy involves the percutaneous injection of an ethanol gel into the degenerated disk’s nucleus pulposus. This paper compares the 1-year outcome of such t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kajetan Latka, Klaudia Kozlowska, Marek Waligora, Waldemar Kolodziej, Tomasz Olbrycht, Jacek Chowaniec, Stanislaw Hendryk, Miroslaw Latka, Dariusz Latka
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	chemonucleolysis discogenic pain ethanol gel low back pain percutaneous spine surgery radiculopathy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/c573c9bb41b64720be89329152f05f64
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c573c9bb41b64720be89329152f05f64
record_format	dspace
spelling	oai:doaj.org-article:c573c9bb41b64720be89329152f05f642021-11-25T16:57:12ZEfficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients10.3390/brainsci111114342076-3425https://doaj.org/article/c573c9bb41b64720be89329152f05f642021-10-01T00:00:00Zhttps://www.mdpi.com/2076-3425/11/11/1434https://doaj.org/toc/2076-3425Patients with degenerative disc disease may suffer from chronic lumbar discogenic (DP) or radicular leg (RLP) pain. Minimally invasive DiscoGel therapy involves the percutaneous injection of an ethanol gel into the degenerated disk’s nucleus pulposus. This paper compares the 1-year outcome of such treatment in DP and RLP patients. We operated on 67 patients (49 men and 18 women) aged 20–68 years (mean age 46 ± 11 years) with DP (<i>n</i> = 45) and RLP (<i>n</i> = 22), of at least 6–8 weeks duration, with no adverse effects. We evaluated the treatment outcome with Core Outcome Measures Index (COMI) and Visual Analog Scale (VAS). A year after the ethanol gel injection, in the DP cohort, COMI and VAS dropped by 66% (6.40 vs. 2.20) and 53% (6.33 vs. 2.97), respectively. For the RLP patients, the corresponding values dropped 48% (7.05 vs. 3.68) and 54% (6.77 vs. 3.13). There were no differences between the cohorts in COMI and VAS at the follow-up end. Six months into the study, 74% of DP and 81% of RLP patients did not use any analgesics. Ethanol gel therapy can be effective for many patients. Moreover, its potential failure does not exclude surgical treatment options.Kajetan LatkaKlaudia KozlowskaMarek WaligoraWaldemar KolodziejTomasz OlbrychtJacek ChowaniecStanislaw HendrykMiroslaw LatkaDariusz LatkaMDPI AGarticlechemonucleolysisdiscogenic painethanol gellow back painpercutaneous spine surgeryradiculopathyNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENBrain Sciences, Vol 11, Iss 1434, p 1434 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemonucleolysis discogenic pain ethanol gel low back pain percutaneous spine surgery radiculopathy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	chemonucleolysis discogenic pain ethanol gel low back pain percutaneous spine surgery radiculopathy Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Kajetan Latka Klaudia Kozlowska Marek Waligora Waldemar Kolodziej Tomasz Olbrycht Jacek Chowaniec Stanislaw Hendryk Miroslaw Latka Dariusz Latka Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients
description	Patients with degenerative disc disease may suffer from chronic lumbar discogenic (DP) or radicular leg (RLP) pain. Minimally invasive DiscoGel therapy involves the percutaneous injection of an ethanol gel into the degenerated disk’s nucleus pulposus. This paper compares the 1-year outcome of such treatment in DP and RLP patients. We operated on 67 patients (49 men and 18 women) aged 20–68 years (mean age 46 ± 11 years) with DP (<i>n</i> = 45) and RLP (<i>n</i> = 22), of at least 6–8 weeks duration, with no adverse effects. We evaluated the treatment outcome with Core Outcome Measures Index (COMI) and Visual Analog Scale (VAS). A year after the ethanol gel injection, in the DP cohort, COMI and VAS dropped by 66% (6.40 vs. 2.20) and 53% (6.33 vs. 2.97), respectively. For the RLP patients, the corresponding values dropped 48% (7.05 vs. 3.68) and 54% (6.77 vs. 3.13). There were no differences between the cohorts in COMI and VAS at the follow-up end. Six months into the study, 74% of DP and 81% of RLP patients did not use any analgesics. Ethanol gel therapy can be effective for many patients. Moreover, its potential failure does not exclude surgical treatment options.
format	article
author	Kajetan Latka Klaudia Kozlowska Marek Waligora Waldemar Kolodziej Tomasz Olbrycht Jacek Chowaniec Stanislaw Hendryk Miroslaw Latka Dariusz Latka
author_facet	Kajetan Latka Klaudia Kozlowska Marek Waligora Waldemar Kolodziej Tomasz Olbrycht Jacek Chowaniec Stanislaw Hendryk Miroslaw Latka Dariusz Latka
author_sort	Kajetan Latka
title	Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients
title_short	Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients
title_full	Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients
title_fullStr	Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients
title_full_unstemmed	Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients
title_sort	efficacy of discogel in treatment of degenerative disc disease: a prospective 1-year observation of 67 patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c573c9bb41b64720be89329152f05f64
work_keys_str_mv	AT kajetanlatka efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT klaudiakozlowska efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT marekwaligora efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT waldemarkolodziej efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT tomaszolbrycht efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT jacekchowaniec efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT stanislawhendryk efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT miroslawlatka efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients AT dariuszlatka efficacyofdiscogelintreatmentofdegenerativediscdiseaseaprospective1yearobservationof67patients
_version_	1718412861833740288

Efficacy of DiscoGel in Treatment of Degenerative Disc Disease: A Prospective 1-Year Observation of 67 Patients

Ejemplares similares